ReviewThe FEBS journal2026
Interactions between small leucine-rich proteoglycans and proteases: implications for tissue homeostasis and pathology.
Review in The FEBS journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Small leucine-rich proteoglycans (SLRPs) are essential regulators of extracellular matrix (ECM) organization and cell signaling. Beyond their structural roles, SLRPs modulate protease activity or serve as their substrates, thereby influencing key physiological processes such as collagen fibrillogenesis, wound healing, skeletal development, and immune surveillance. On the other hand, the dysregulation of SLRP-protease interactions, in pathologies such as fibrosis, chronic inflammation, and cancer, results in aberrant ECM remodeling, immune activation, and altered cell behavior. Here, we review emerging insights into the functional crosstalk between SLRPs and proteases in health and disease. We highlight how these interactions impact tissue integrity and disease progression and explore their potential as diagnostic markers and therapeutic targets in fibrosis, cancer, and inflammatory disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.